<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909789</url>
  </required_header>
  <id_info>
    <org_study_id>21835-01</org_study_id>
    <nct_id>NCT03909789</nct_id>
  </id_info>
  <brief_title>Effect of Inorganic Nitrate Supplement on Blood Pressure</brief_title>
  <official_title>Acute and Sustained Effects of Plant- Based Bio-Equivalent Nitrate Supplement Tablets on Blood Pressure Reduction, Nitric Oxide Mediated Endothelial Function and Saliva Bioconversion of Dietary Nitrate in Hypertensive Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this project is to assess the efficacy (effectiveness) of plant-based&#xD;
      nitrate tablets to elevate nitric oxide in your system as measured by saliva and effect on&#xD;
      lowering blood pressure (BP), supporting blood vessel function in men and women with&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is to assess the efficacy of plant-based bioequivalent Nitric Oxide&#xD;
      supplement for improving blood pressure and endothelial reactivity over a 12 weeks&#xD;
      intervention period in individuals with metabolic syndrome. The study also examines the&#xD;
      effect of plant-based bioequivalent Nitric Oxide supplement on other markers of&#xD;
      cardiovascular function and cardiovascular disease risk including Total, LDL and&#xD;
      HDL-Cholesterol, Triglycerides, and a multitude of inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Actual">June 22, 2018</completion_date>
  <primary_completion_date type="Actual">June 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Placebo Controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in blood pressure (in millimeters of mercury) over twelve weeks under effect of active treatment and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in serum, plasma and salivary Nitrite and Nitrate</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in serum nitrate and nitrate levels (in mcg) over 12 weeks comparing active treatment to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiometabolic relevant biomarkers (as compared to placebo)</measure>
    <time_frame>12 weeks</time_frame>
    <description>measures of serum markers of inflammation (Crp) and glucose over 12 weeks in active vs placebo arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>plant based bioequivalent dietary nitrate supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo does not contain any nitric oxide supplement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plant based bioequivalent Nitrate supplementation</intervention_name>
    <description>The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.</description>
    <arm_group_label>plant based bioequivalent dietary nitrate supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 40-75 years&#xD;
&#xD;
          -  Hypertension &gt;130/85 mmHg; men and women, 1:1 and stable medicated hypertensives&#xD;
&#xD;
          -  Subjects must provide written informed consent after the scope and nature of the&#xD;
             investigation has been explained to them&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of&#xD;
             the investigator or principal investigator is likely to affect the subject's ability&#xD;
             to complete the study or precludes the subject's participation in the study&#xD;
&#xD;
          -  Weight in excess of 250 pounds&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  History of known coronary artery disease, myocardial infarction, stroke or&#xD;
             life-threatening arrhythmia within the prior six months&#xD;
&#xD;
          -  NYHA Class II- IV heart failure&#xD;
&#xD;
          -  History of malignancy within the last 5 years (other than skin cancer) or evidence of&#xD;
             active cancer which would require concomitant cancer chemotherapy&#xD;
&#xD;
          -  Serum creatinine &gt; 1.4 mg/dl&#xD;
&#xD;
          -  Triglycerides &gt; 400 at visit 1&#xD;
&#xD;
          -  Drug or alcohol abuse, or current intake of more than 14 standard drinks per week&#xD;
&#xD;
          -  Concurrent enrollment in another placebo-controlled trial&#xD;
&#xD;
          -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption&#xD;
&#xD;
          -  Current tobacco use&#xD;
&#xD;
          -  Current use of anticoagulants (except for anti-platelet agents)&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident&#xD;
&#xD;
          -  Hematological or biochemical values at screening outside the reference ranges&#xD;
             considered as clinically significant in the opinion of the investigator or PI&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Endothelium</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

